{"component": "definition", "props": {"groups": [{"snippet": "means Athyrium Capital Management, LP and its successors and assigns.", "size": 30, "snippet_links": [{"key": "capital-management", "type": "clause", "offset": [15, 33]}, {"key": "successors-and-assigns", "type": "definition", "offset": [46, 68]}], "samples": [{"hash": "z3t1GLlbO9", "uri": "/contracts/z3t1GLlbO9#athyrium", "label": "Credit Agreement (Esperion Therapeutics, Inc.)", "score": 35.9486656189, "published": true}, {"hash": "iyleNoaNwW7", "uri": "/contracts/iyleNoaNwW7#athyrium", "label": "Credit Agreement (Calliditas Therapeutics AB)", "score": 35.3107452393, "published": true}, {"hash": "gHoP3bqwTj6", "uri": "/contracts/gHoP3bqwTj6#athyrium", "label": "Note Purchase Agreement (RVL Pharmaceuticals PLC)", "score": 33.6078033447, "published": true}], "hash": "c49b2297beb11d62a57bcfa4fade012a", "id": 1}, {"snippet": "means Athyrium Capital Management, LLC.", "size": 7, "snippet_links": [{"key": "capital-management", "type": "clause", "offset": [15, 33]}], "samples": [{"hash": "a2KGNH1sBrt", "uri": "/contracts/a2KGNH1sBrt#athyrium", "label": "Credit Agreement (Syncardia Systems Inc)", "score": 26.623544693, "published": true}, {"hash": "67gCqIpjDDU", "uri": "/contracts/67gCqIpjDDU#athyrium", "label": "Second Lien Credit Agreement (Syncardia Systems Inc)", "score": 26.623544693, "published": true}, {"hash": "9yHgPQCqvZV", "uri": "/contracts/9yHgPQCqvZV#athyrium", "label": "Credit Agreement (Verenium Corp)", "score": 24.5756340027, "published": true}], "hash": "a60e61693dba40e9b9ec3998672b8f3b", "id": 2}, {"snippet": "means Athyrium Buffalo LP.", "size": 6, "snippet_links": [], "samples": [{"hash": "ezL3KPQmV6l", "uri": "https://www.annualreports.com/HostedData/AnnualReportArchive/r/NASDAQ_RVNC_2022.pdf", "label": "www.annualreports.com", "score": 20.01927948, "published": false}, {"hash": "lgDiC6ydkuV", "uri": "https://s202.q4cdn.com/113424049/files/doc_financials/2023/q4/fdc51f74-a336-4099-b6e0-3a3e7ebfe7a1.pdf", "label": "s202.q4cdn.com", "score": 19.3182258606, "published": false}, {"hash": "1HF248S4cPW", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/05482217-c985-49d0-bfb9-0f65b4959c4c.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 19.2786121368, "published": false}], "hash": "9ac4a51c46db237068034e703fdb4003", "id": 3}, {"snippet": "as defined in the Preamble.", "size": 4, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [14, 26]}], "samples": [{"hash": "dMzhfi260wr", "uri": "/contracts/dMzhfi260wr#athyrium", "label": "Registration Rights Agreement (Amryt Pharma PLC)", "score": 31.4750175476, "published": true}, {"hash": "6YC7NiRMq5Y", "uri": "/contracts/6YC7NiRMq5Y#athyrium", "label": "Registration Rights Agreement (Amryt Pharma PLC)", "score": 31.3572902679, "published": true}, {"hash": "4pTWutRZMUF", "uri": "/contracts/4pTWutRZMUF#athyrium", "label": "Registration Rights Agreement", "score": 23.8158798218, "published": true}], "hash": "f12cc7c21a537ec433eed52756606a70", "id": 4}, {"snippet": "means Athyrium Opportunities II Acquisition LP, a Delaware limited partnership and Athyrium Opportunities III Acquisition LP, a Delaware limited partnership;", "size": 3, "snippet_links": [{"key": "acquisition-lp", "type": "definition", "offset": [32, 46]}, {"key": "delaware-limited-partnership", "type": "clause", "offset": [50, 78]}], "samples": [{"hash": "gxU17IpyFl7", "uri": "/contracts/gxU17IpyFl7#athyrium", "label": "Plan Funding Agreement (Amryt Pharma PLC)", "score": 31.4750175476, "published": true}, {"hash": "j9lAkk1Anxk", "uri": "/contracts/j9lAkk1Anxk#athyrium", "label": "Plan Funding Agreement (Novelion Therapeutics Inc.)", "score": 30.3826141357, "published": true}, {"hash": "9SL3YFqLV1v", "uri": "https://cases.primeclerk.com/aegerion/Home-DownloadPDF?id1=MTEyMTcyNQ==&id2=0", "label": "cases.primeclerk.com", "score": 9.6899385452, "published": false}], "hash": "7cee6748bf8ad77aa261aefb4e8fb36b", "id": 5}, {"snippet": "means Athyrium Opportunities III Co-Invest 1 LP, together with its successors in such capacity.", "size": 3, "snippet_links": [], "samples": [{"hash": "1hyUN4FkJSF", "uri": "https://www.sec.gov/Archives/edgar/data/882796/000117184321001411/ex_230714.htm", "label": "Purchase and Sale Agreement (Biocryst Pharmaceuticals Inc)", "score": 23.1622180939, "published": false}, {"hash": "grWJizmy1Gg", "uri": "https://www.sec.gov/Archives/edgar/data/882796/000117184322001460/ex_340700.htm", "label": "Purchase and Sale Agreement (Biocryst Pharmaceuticals Inc)", "score": 21.1587944031, "published": false}, {"hash": "ebMvfSdPlsl", "uri": "https://www.sec.gov/Archives/edgar/data/882796/000117184322001460/ex_340699.htm", "label": "Purchase and Sale Agreement (Biocryst Pharmaceuticals Inc)", "score": 21.1587944031, "published": false}], "hash": "c281f433e8f7280949f8ea4d527a9745", "id": 6}, {"snippet": "has the meaning given thereto in the recitals of this Agreement;", "size": 2, "snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [33, 45]}, {"key": "this-agreement", "type": "clause", "offset": [49, 63]}], "samples": [{"hash": "37gszumrJtW", "uri": "/contracts/37gszumrJtW#athyrium", "label": "Relationship Agreement (Agendia N.V.)", "score": 32.8220405579, "published": true}, {"hash": "cnpSb24IWUi", "uri": "/contracts/cnpSb24IWUi#athyrium", "label": "Relationship Agreement (Agendia N.V.)", "score": 32.761806488, "published": true}], "hash": "23e268073a390827e8da89a2ab50c032", "id": 7}, {"snippet": "means Athyrium Buffalo LP. \u201cATM\u201d means at-the-market offering program. \u201cBLA\u201d means a biologics license application.", "size": 2, "snippet_links": [{"key": "biologics-license-application", "type": "clause", "offset": [85, 114]}], "samples": [{"hash": "5hQvQnG5Dxy", "uri": "https://investors.revance.com/files/doc_financials/2023/q2/0001479290-23-000093.pdf", "label": "investors.revance.com", "score": 11.8624229431, "published": false}, {"hash": "7yUBq144KS6", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/aa6e0129-ed06-4035-9b53-8c87d61978d6.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 10.1868581772, "published": false}], "hash": "3e86e26072756aea4417cb2e0199182a", "id": 8}, {"snippet": "means Athyrium Buffalo LP. \u201cATM\u201d means at-the-market offering program. \u201cBLA\u201d means a biologics license application. \u201cBofA\u201d means Bank of America, N.A.", "size": 2, "snippet_links": [{"key": "biologics-license-application", "type": "clause", "offset": [85, 114]}, {"key": "bank-of-america", "type": "clause", "offset": [129, 144]}], "samples": [{"hash": "5AFajHESIs8", "uri": "https://s202.q4cdn.com/113424049/files/doc_financials/2023/q1/Q123-10Q.pdf", "label": "s202.q4cdn.com", "score": 17.0812702179, "published": false}, {"hash": "kR0SS9NeVaa", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d0ad0b23-7f95-4ee3-8f56-1f310f2d622b.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 9.9308691025, "published": false}], "hash": "0237537baf193cc852f2799cf99def52", "id": 9}, {"snippet": "means, collectively and individually, (i) Athyrium Capital Management, LLC and (ii) Athyrium Opportunities Advisers LLC.", "size": 2, "snippet_links": [{"key": "capital-management", "type": "clause", "offset": [51, 69]}], "samples": [{"hash": "6LheCfAEkov", "uri": "/contracts/6LheCfAEkov#athyrium", "label": "Credit Agreement (Universal Biosensors Inc)", "score": 24.9671459198, "published": true}, {"hash": "2HdfDn2qkxi", "uri": "https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-13-480844.html?hash=748f88511d89e2e23c260d96c04cc905a4a581ebcada526fc0c19893b7f282cc&dest=D647888DEX102_HTM", "label": "content.edgar-online.com", "score": 10.1704311371, "published": false}], "hash": "089125eea664df07677a6f3becc39623", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRYXRoeXJpdW0jMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means Athyrium Capital Management, LP and its successors and assigns.", "title": "Athyrium", "size": 67, "id": "athyrium", "examples": ["To the fullest extent permitted by law, the Borrower hereby waives and releases, any claims that it may have against the Administrative Agent, <strong>Athyrium</strong> or any Lender with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.", "It is understood and agreed that <strong>Athyrium</strong>, the Administrative Agent and the Purchasers reserve the right to allocate, in whole or in part, to their respective Affiliates, the fees and original issue discount payable to such Persons hereunder in such manner as <strong>Athyrium</strong>, the Administrative Agent, the Purchasers and such Affiliates shall agree in their sole discretion.", "Receipt by <strong>Athyrium</strong>, the Administrative Agent and the Lenders of any fees required to be paid on or before the Closing Date.", "It is understood and agreed that <strong>Athyrium</strong>, the Administrative Agent and the Lenders reserve the right to allocate, in whole or in part, to their respective Affiliates, the fees payable to such Persons hereunder in such manner as <strong>Athyrium</strong>, the Administrative Agent, the Lenders and such Affiliates shall agree in their sole discretion.", "To the fullest extent permitted by law, the Issuer hereby waives and releases, any claims that it may have against the Administrative Agent, <strong>Athyrium</strong> or any Purchaser with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.", "This Series B Preferred Stock Purchase Warrant (this \u201cWarrant\u201d) is issued under and pursuant to that certain Credit and Security Agreement, dated as of the Issuance Date, by and among the Company, as borrower, the lenders party thereto, and <strong>Athyrium</strong> Opportunities III Co-Invest 1 LP, as collateral agent (as amended, modified, restated, refinanced, replaced or supplemented from time to time, the \u201cCredit Agreement\u201d).", "The Company shall, subject to prior compliance with Section 4(b)(i), within fifteen (15) Business Days after the date of the notice from Highbridge or <strong>Athyrium</strong>, ensure that the person so nominated is proposed for appointment or reappointment (as the case may be) as a Director, at a meeting of the Board by way of resolution of the Board or by a written resolution of the Directors and that such appointment is approved at the next meeting of the shareholders of the Company.", "<strong>ATHYRIUM</strong> OPPORTUNITIES FUND (A) LP, a Delaware limited partnership By: <strong>ATHYRIUM</strong> OPPORTUNITIES ASSOCIATES LP, its General Partner By: <strong>ATHYRIUM</strong> OPPORTUNITIES ASSOCIATES GP LLC, the General Partner of <strong>Athyrium</strong> Opportunities Associates LP By: /s/ \u2587\u2587\u2587\u2587\u2587\u2587 \u2587.", "To the fullest extent permitted by law, the Issuers hereby waive and release, any claims that they may have against the Collateral Agent, <strong>Athyrium</strong> or any Purchaser with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.", "Receipt by <strong>Athyrium</strong>, the Collateral Agent and the Purchasers of any fees required to be paid on or before the Closing Date."], "related": [["gso", "GSO", "GSO"], ["crp", "CRP", "CRP"], ["lp", "LP", "LP"], ["epfo", "EPFO", "EPFO"], ["insight", "Insight", "Insight"]], "related_snippets": [], "updated": "2026-04-05T05:49:25+00:00"}, "json": true, "cursor": ""}}